ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Limited has rescheduled its 38th Annual General Meeting to September 29, 2026. Consequently, the record date for the FY 2025-26 dividend is revised to September 22, 2026.
N. Srilakshmi Padmini, an employee's immediate relative, purchased 3,000 equity shares of SMS Pharmaceuticals for ₹0.11 Crore via market purchase.
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals reported Q1FY27 revenue of ₹207 crore, up 6% YoY. The board also approved a ₹50 crore loan infusion into its subsidiary, SMS Peptides.
SMS Pharmaceuticals has re-appointed Mr. Ramesh Babu Potluri as Executive Director for a 60-month term effective October 1, 2026.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹207 Cr (+5.6% YoY) and net profit of ₹20.9 Cr (+2.0% YoY) for Q1 FY27.
SMS Pharmaceuticals has scheduled a board meeting for August 1, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
SMS Pharmaceuticals updated the exchange regarding an ongoing police investigation into a prior impersonation case. One suspect has been arrested and remanded into judicial custody.
SMS Pharmaceuticals clarified the recent surge in its share volume, stating it is driven solely by market conditions. No material information has been withheld.
SMS Pharmaceuticals detected fraudulent transfers of 85,000 physical shares involving forged documents. The company filed a complaint with the Economic Offences Wing to safeguard shareholder interests.
SMS Pharma delivered FY26 revenue of ₹887cr (+13%) and PAT of ₹102cr (+47%). Strategy focuses on backward integration and high-margin API expansion.
SMS Pharma reported strong FY26 performance with PAT reaching ₹102 crore (up 48% YoY) and EBITDA margins expanding to 19%.
SMS Pharmaceuticals reported FY26 revenue of ₹886.87 Crore, a 13% YoY increase. Net profit surged 47% to ₹101.98 Crore, driven by backward integration and mix.
SMS Pharmaceuticals Limited recommended a final dividend of ₹0.4 per equity share for 2026. This distribution rewards shareholders while the AGM date remains pending.
SMS Pharmaceuticals re-appointed Annapragada & Co. as cost auditors and Adusumilli & Associates as internal auditors. Both appointments are for a twelve-month term.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹237.9 Cr (-4.1% YoY) and net profit of ₹32.7 Cr (+61.1% YoY) for Q4 FY26.
SMS Pharmaceuticals reported audited FY26 results and recommended a ₹0.40 per share final dividend. The company also approved shifting its registered office within Hyderabad.
SMS Pharmaceuticals scheduled a board meeting for May 22, 2026, to approve annual audited results and final dividend. Trading window remains closed until May 24, 2026.
SMS Pharmaceuticals Limited confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026, per SEBI framework. Consequently, provisions for initial and annual disclosures regarding fund raising through debt securities are not applicable to the company.
SMS Pharmaceuticals Limited received a rectification order from the Income Tax Department for AY 2018-19. The order significantly reduces the company's tax demand from ₹7.19 Crore to ₹40.28 Lakhs. The company is reevaluating further steps and states there is no material impact on its financial or operational activities.
SMS Pharmaceuticals Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent confirmed the dematerialization and cancellation of security certificates. This is a routine administrative filing with no material financial impact.